Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer

Figures & data

Table 1 Clinicopathological parameters of 281 patients with triple-negative breast cancer

Parameters	N=281	%
Age (years)
≤50	201	72
>50	80	28
Type of surgery
Breast-conserving surgery	46	16
Radical mastectomy	235	84
Tumor stage
pT1	59	21
pT2	167	59
pT3	50	18
pT4	5	2
Tumor histology
Invasive ductal carcinoma	223	79
Invasive lobular carcinoma	55	20
Others	3	1
Lymphovascular invasion
Yes	39	14
No	242	86
Histological grade
I–II	181	64
III	100	36
Ki-67
≥30%	121	43
<30%	160	57
Lymph node status
pN0	118	42
pN1	96	34
pN2	41	15
pN3	26	9
AJCC stage
I	39	14
II	150	54
III	92	33
Adjuvant radiotherapy
Yes	180	64
No	101	36
Chemotherapy
Neoadjuvant chemotherapy	59	21
Adjuvant chemotherapy	222	79
dNLR
≥2.6	109	39
<2.6	172	61

Abbreviations: AJCC, American Joint Committee on Cancer; dNLR, derived neutrophil-to-lymphocyte ratio.

Figure 1 The disease-free survival in TNBC patients divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Figure 2 The overall survival in TNBC patients divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Figure 3 The disease-free survival in TNBC patients aged ≤50 years divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Figure 4 Overall survival of TNBC patients aged ≤50 years divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Figure 5 The disease-free survival in TNBC patients with invasive ductal carcinoma divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Figure 6 The overall survival in TNBC patients with invasive ductal carcinoma divided by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; TNBC, triple-negative breast cancer.

Table 2 Cox analysis for disease-free survival in 281 patients with triple-negative breast cancer

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Age (years)
>50 vs ≤50	0.69	0.56–1.09	0.196	0.69	0.51–1.18	0.105
Type of surgery
Radical mastectomy vs breast conserving surgery	1.05	0.91–1.12	0.244	0.92	0.84–1.24	0.379
Tumor stage
T2–4 vs T1	1.69	1.16–2.59	0.006	1.50	1.31–2.49	0.015
Lymphovascular invasion
Yes vs no	1.24	1.09–1.76	0.021	1.01	0.92–1.26	0.152
Histological grade
III vs I–II	2.31	1.92–3.16	<0.001	2.01	1.35–2.59	0.011
Lymph node status
Yes vs no	1.94	1.46–2.38	0.004	1.19	1.16–1.86	0.059
Adjuvant radiotherapy
Yes vs no	0.77	0.69–1.12	0.587	0.72	0.64–1.07	0.659
Chemotherapy
Neoadjuvant vs adjuvant	0.84	0.72–1.15	0.489	0.77	0.69–1.12	0.575
dNLR
≥2.6 vs <2.6	2.39	1.85–2.59	<0.001	1.90	1.52–2.46	0.007

Abbreviation: dNLR, derived neutrophil-to-lymphocyte ratio.

Table 3 Cox analysis for overall survival in 281 patients with triple-negative breast cancer

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Age (years)
>50 vs ≤50	0.82	0.62–1.15	0.354	0.77	0.51–1.26	0.325
Type of surgery
Radical mastectomy vs breast conserving surgery	1.10	0.82–1.31	0.292	0.98	0.79–1.06	0.453
Tumor stage
T2–4 vs T1	2.43	1.79–3.26	<0.001	1.78	1.31–2.84	0.002
Lymphovascular invasion
Yes vs no	1.50	1.18–1.86	0.017	1.31	1.07–1.62	0.047
Histological grade
III vs I–II	3.12	2.62–3.51	<0.001	2.30	1.75–2.84	0.004
Lymph node status
Yes vs no	2.52	1.76–3.15	0.002	1.86	1.46–2.54	0.018
Adjuvant radiotherapy
Yes vs no	0.88	0.65–1.12	0.837	0.80	0.62–1.08	0.875
Chemotherapy
Neoadjuvant vs adjuvant	0.92	0.81–1.16	0.860	0.83	0.68–1.12	0.926
dNLR
≥2.6 vs <2.6	3.13	1.86–4.26	<0.001	2.56	1.69–3.58	0.001

Abbreviation: dNLR, derived neutrophil-to-lymphocyte ratio.

Figure S1 ROC curve to distinguish long and short OS by dNLR.

Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; OS, overall survival; ROC, receiver operating characteristic curve; AUC, area under the curve.